TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02501629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab 110 mg was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
Study: NCT03452202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix 1x1 line tDCS low-intensity stimulator
Description: Introduction of the independent variable (treatment) across three different points in time. Participants will be randomly assigned to have each treatment phase begin after 3, 4, or 6 baseline sessions. This current stimulates the cortex, with anodal stimulation leading to a depolarized state in which neurons are more likely to fire.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Soterix 1x1 line tDCS low-intensity stimulator
Description: Introduction of the independent variable (treatment) across three different points in time. Participants will be randomly assigned to have each treatment phase begin after 3, 4, or 6 baseline sessions. This current stimulates the cortex, with anodal stimulation leading to a depolarized state in which neurons are more likely to fire.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Patients will have two electrodes applied (one anode, one cathode) administering no stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Patients will have two electrodes applied (one anode, one cathode) administering no stimulation
Study: NCT01713244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA assisted Hepatectomy
Description: Using RFA to ablate and block the small vessels around the tumor before resection to reduce the spreading of the cancer cell.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatectomy
Description: Treat the advanced HCC with the hepatectomy only.
Study: NCT02722330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baha 5 SuperPower on Baha Attract System
Description: The Investigational device involves the following parts: the sound processor unit, an actuator unit and a cable that connects the sound processor and actuator units. The actuator unit is attached to the Sound Processor Magnet (SP Magnet) of the Baha Attract System which is pulled towards the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant. The actuator unit can also be connected to the Baha Softband via a snap coupling.
Study: NCT01334567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Description: Provision of tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablets, as prescribed by study investigators
Study: NCT01172236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: Experimental group: newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.~Control group: newborns (group B) will receive only standard therapy and they will be used as controls.
Study: NCT02501629

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-Oral Corticosteroid (non-OCS) Asthma Medication
Description: Participants continue using their non-OCS background asthma medications without change during the study's treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-Oral Corticosteroid (non-OCS) Asthma Medication
Description: Participants continue using their non-OCS background asthma medications without change during the study's treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Corticosteroid (OCS)
Description: After screening and prior to study start, the participant's OCS dose was adjusted to determine the minimal effective OCS requirement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Corticosteroid (OCS)
Description: After screening and prior to study start, the participant's OCS dose was adjusted to determine the minimal effective OCS requirement.
Study: NCT04501224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide fumarate
Description: Patients would take tenofovir alafenamide fumarate, 25mg，once per day
Study: NCT01172236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: Experimental group: 650 newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.Control group: 650 newborns (group B) will receive only standard therapy and they will be used as controls.
Study: NCT06746389

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 3000 IU per Day Spray
Description: Effects of vitamin D supplementation vs placebo on MPS in response to exercise and feeding

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3000 IU per Day Spray
Description: Effects of vitamin D supplementation vs placebo on MPS in response to exercise and feeding
Study: NCT04501224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir or Tenofovir disoproxil fumarate
Description: Patients would take entecavir 0.5 mg once per day, or tenofovir disoproxil fumarate 300 mg once per day
Study: NCT02726750

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01910948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 polyunsaturated fatty acids
Description: The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
Study: NCT04414748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of COH till the day of the ovulation trigger

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Duphaston
Description: oral Duphaston 10mg bd from Day 3 of COH till the day of ovulation trigger.
Study: NCT00252746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib) 100mg
Description: once daily oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib) 200mg
Description: once daily oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib) 300mg
Description: once daily oral dose
Study: NCT01354587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hizentra
Description: Subjects transition from Vivaglobin to Hizentra using weekly subcutaneous infusions for 32 weeks.
Study: NCT02429843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: Each patient will be dosed with 6, 8, or 10 mg/kg of TRC105 up to a maximum dose of 850 mg for women and 1,000 mg for men based upon overall body weight.
Study: NCT03259217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem Cell Product
Description: Adipose tissue derived mesenchymal stem cell seeded in Curcumin loaded chitosan nanoparticles into collagen-alginate
Study: NCT01219673

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 by mouth twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 150 mg by mouth once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 150 mg by mouth once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 150 mg by mouth once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 150 mg by mouth once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg by mouth twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg by mouth twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg by mouth twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg by mouth twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 100 mg by mouth twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 100 mg by mouth twice a day.
Study: NCT03345550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules.
Description: Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules.
Study: NCT01530074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary blocking of mandibular nerve
Description: IM. Lidocaine 2% 7.2ML
Study: NCT02851030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move, Play, Learn!
Description: Participants will attend a 4 hour workshop at the beginning of the intervention and the midpoint, covering project information, physical activity for young children, and distribution of project materials. Teachers will focus on one area of their child care day for 2 weeks each: indoor structured PA, outdoor structured PA, transitions between activities, and circle time. Participants will receive an email newsletter introducing the topic and will implement short (10 minutes) classroom activities. Teachers will also be educated about teacher PA practices, focusing on 1 behavior during each segment. Research staff will contact the teachers weekly to provide technical assistance, help teachers troubleshoot any issues that participants have with the activities, and provide encouragement.
Study: NCT00731107

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic surgery
Description: XCEL bladeless trocar laparoscopic entry

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic surgery
Description: Veress Needle laparoscopic entry
Study: NCT02799212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatostatin infusion
Description: postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion
Description: Placebo infusion (50ml of 0.9% NaCl/day) during 6 days.
Study: NCT03997006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Aminophylline
Description: IV Aminophylline (100 mg/8h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Neostigmine Methylsulfate + Atropine Sulphate
Description: IV Neostigmine/Atropine mixture (20 μg/kg Neostigmine + 10 μg/kg Atropine)/8h
Study: NCT02911064

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires completed before and after inpatient rehabilitation. Questionnaires ask about daily living activity performance, expectation of how well daily living activities will be performed after completion of inpatient rehabilitation, symptoms experienced in the past 24 hours, and physical, functional, social, and emotional well-being. These questionnaires should take about 15 minutes total to complete.
Study: NCT03801434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study: NCT03759379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patisiran
Description: Patisiran will be administered by IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vutrisiran
Description: Vutrisiran will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vutrisiran
Description: Vutrisiran will be administered by SC injection.
Study: NCT03345550

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules (olive oil capsules that look identical to the intervention DHA+EPA).
Study: NCT04883203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit-D 0.2 MG/ML Oral Solution [Calcidol]
Description: ARM 1 : Cholecalciferol 200,000 IU / 1 mL .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological Irrigating Solution
Description: ARM 2 : placebo
Study: NCT01631500

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional treatment
Description: Conventional treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative treatment
Description: Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic acupuncture
Description: Eight individual sessions, once a week, with therapeutic acupuncture. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
Study: NCT03701074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen and acetaminophen
Description: Intravenous ibuprofen given concomitantly with oral acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen and placebo
Description: Intravenous ibuprofen given concomitantly with oral placebo
Study: NCT02174237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP1892
Description: Tablets of two strengths (5 and 25 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01339091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin / Linezolid
Description: IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.
Study: NCT06316765

Intervention type: PROCEDURE
Intervention: Intubation with stylet
Description: The cohort of premature infants was intubated with stylet.
Study: NCT04390230

Intervention type: PROCEDURE
Intervention: Penile prostheses implantation
Description: Penial implantation with either Coloplast or Boston Scientific - AMS IPPs between 2014 and 2019, by 2 surgeons of the University Hospital of Nice, France
Study: NCT01219673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 100 mg by mouth twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 100 mg by mouth twice a day.
Study: NCT01630057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjunctive Zonisamide
Description: Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Replacement with Zonisamide
Description: Patients will continue to receive zonisamide as third drug
Study: NCT03913468

Intervention type: DRUG
Intervention: Intravenous Ascorbic Acid
Description: 1.5 grams IV ascorbic acid q6h, 50 mg IV hydrocortisone q 6 hours, and 200mg IV thiamine BID administered (as documented in medical record)
Study: NCT00347360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol controlled release formulation
Study: NCT03745807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT01047670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
Study: NCT00913380

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diagnostic CT
Description: 2 mSv in an average patient (Low-dose (1/4 to 1/5 of standard-dose))
Study: NCT03934294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific acupuncture group
Description: In addition to routine ICU treatments, patients in the specific acupuncture group will also receive daily bilateral traditional Chinese medicine style acupuncture on the following acupuncture points: ST36 (Zu San Li), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Nei Guan) and LI4 (He Gu). The acupoints indications in this group are specific to treat indigestion related conditions. The treatment will take place once a day, over three days, for a total of three treatments. A total of 10 Needles will be used in each session Acupuncture treatment will be performed with sterile needles manufactured by Yu Kuang acupuncture needles 40mm with 30G.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoclopramide 10mg
Description: Patients in all groups will receive Metoclopramide 10mg/ per 8 hours in the case of poor digestion, alongside the individualized drug treatment prescribed by the ICU medical doctor as per individual patient needs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10mg
Description: Patients in all groups will receive Metoclopramide 10mg/ per 8 hours in the case of poor digestion, alongside the individualized drug treatment prescribed by the ICU medical doctor as per individual patient needs.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-specific acupuncture group
Description: Patients' in the non-specific acupuncture group (Con-Acu) will receive routine ICU treatment as well as a total of 3 daily non digestion related Traditional Chinese medicine style acupuncture treatments at the following acupoints: LI 15 (Jianyu), SJ 14 (JianLiao) LU3 (Tianfu), GB35 (Yangjiao), BL 59 (Fuyang). The selected control points are not indicated for the treatment of digestion related conditions, and are not reported to improve digestive function.
Study: NCT04370886

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: blood donation SMS
Description: The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blood donation SMS
Description: The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blood donation SMS
Description: The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blood donation SMS
Description: The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
Study: NCT01312298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Patients will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia
Description: Patients will receive intrathecal anesthesia
Study: NCT01242384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Silicon ring (Arabin Pessary)
Description: Placement of a silicon pessary in the vagina, around the cervix.
Study: NCT00558623

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium carbonate
Description: daily supplement of 1,200 milligrams calcium (two-600 mg tablets calcium carbonate at bedtime)
Study: NCT04377776

Intervention type: OTHER
Intervention: Practice details
Description: Questionnaire
Study: NCT04253236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1401 680 mg/weekly
Description: Non-randomized subjects will receive subcutaneous injection of 680 mg weekly for 12 weeks of RVT-1401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1401 340 mg/weekly
Description: Non-randomized subjects will receive subcutaneous injection of 340 mg weekly for 12 weeks of RVT-1401
Study: NCT02115971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jumping exercise
Description: Total 120min exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength exercise
Description: Total 120 min exercise
Study: NCT00583154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-801
Description: Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-801
Description: Dose 2
Study: NCT00913380

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic CT
Description: 8 mSv in an average patient (Standard-dose CT)
Study: NCT00181155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: intravenous infusion of allopurinol (300mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion of 50 ml dose of 5% dextrose
Study: NCT02912078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pocket-warming
Description: Pocket-warming of epidural medication

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Labor Epidural
Description: Labor epidural medication administered per standard of care; no pocket warming.
Study: NCT00004857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: 30 mg subQ injection tiw for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25mg/sq m/day IV infusion x 5 days Wks 1, 5, 9, and 13